Transition Bio provides condensate technology for drug discovery and diagnostics.
Transition Bio has raised $750K in total funding. The most recent round was Grant. The last funding was announced in September 2026.
Transition Bio's investors include Bristol-Myers Squibb, Taiho Ventures, Lifeforce Capital, Northpond Ventures, Magnetic Ventures.
Transition Bio is headquartered in Cambridge, United States.
Transition Bio provides condensate technology for drug discovery and diagnostics.
Transition Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Transition Bio — Funding & Investors." VCBacked, September 10, 2026, https://www.vcbacked.co/company/transition-bio. Accessed October 17, 2026.
VCBacked. (2026). Transition Bio — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/transition-bio
{{cite web |title=Transition Bio — Funding & Investors |url=https://www.vcbacked.co/company/transition-bio |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated